Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a ...

Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...

As such, Novo Nordisk ended its collaboration with Hims & Hers over concerns of illegal mass compounding and deceptive ...

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic ...

At the moment, FP&A in pharma is going through a complex period of change. While new technologies are making it easier to collect and analyze data, external factors are making it much harder to ...